Takeda Emerging Market Strategy Varies From Country To Country: An Interview With PharmAsia News
This article was originally published in PharmAsia News
Takeda’s expansion into emerging markets using its Nycomed acquisition has positioned it well in Russia and Brazil and given Japan’s largest drug maker a small but solid base in China. But its head of international operations says he’s in no rush to expand into India, given the fluid and complex nature of that market.
You may also be interested in...
Takeda and Millennium's recent out-sized tie-up reflects the different but real industry pressures from which both companies are suffering.Facing near-term patent exiprations of several key drugs, Takeda desperately needed to bulk up its R&D pipeline. Millennium, for its own part, was heavily dependent on the label expansion of its lead product, Velcade, as it struggled to maintain sustainable earnings growth and advance its early stage compounds through the clinic.
Emerging Company Profile: Switzerland-based Anjarium Biosciences AG has successfully raised $61m in a series A financing that will fund expansion of its novel proprietary platform and development of a nascent pipeline of non-viral gene therapies.
Incyte welcomed FDA approval of its ruxolitinib cream, a selective JAK1/JAK2 inhibitor, as a treatment for atopic dermatitis, but criticized the boxed warnings label assigned to it.